Immunovant (IMVT) Change in Receivables (2021 - 2026)
Immunovant's (IMVT) quarterly Change in Receivables came in at -$563000.0 in Q1 2026, down 562.35% YoY from $121768.4 in Q1 2025, and down 76.49% on a QoQ basis from -$319000.0 in Q4 2025.
Powered by 
Analysis
Immunovant (IMVT) Change in Receivables (2021 - 2026) Analysis & Trends
Immunovant (IMVT) has 6 years of Change in Receivables data on file, last reported at -$563000.0 in Q1 2026.
- Quarterly Change in Receivables fell 562.35% year-over-year to -$563000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$986000.0 (up 69.49% YoY) and the FY2026 annual result came in at -$986000.0, up 69.49% from the prior year.
- Change in Receivables retreated to -$563000.0 in Q1 2026, from -$319000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $4.1 million in Q1 2024 to a low of -$9.8 million in Q3 2022.
- A 5-year average of -$452352.9 and a median of -$85000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables sank 5616.38% — and 2024, when it jumped 207100.0%.
- Tracing IMVT's Change in Receivables over 5 years: stood at -$2.9 million in 2022, then jumped by 90.97% to -$266000.0 in 2023, then jumped by 174.06% to $197000.0 in 2024, then plunged by 261.93% to -$319000.0 in 2025, then sank by 76.49% to -$563000.0 in 2026.
- The last three Change in Receivables figures came in at -$563000.0 (Q1 2026), -$319000.0 (Q4 2025), and $25000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Immunovant | 8.12 Bn | 8.12 Bn | - | -436,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -436,000.00 |
| Mar 31, 2026 | -563,000.00 |
| Dec 31, 2025 | -319,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | -85,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | -417,000.00 |
| Jun 30, 2024 | -2.93 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Dec 31, 2023 | -266,000.00 |
| Sep 30, 2023 | 561,000.00 |
| Jun 30, 2023 | 142,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Dec 31, 2022 | -2.95 Mn |
| Sep 30, 2022 | -9.76 Mn |
| Jun 30, 2022 | 947,000.00 |
| Mar 31, 2022 | 3.72 Mn |
| Dec 31, 2021 | 7.53 Mn |
| Sep 30, 2021 | 177,000.00 |